Robert Stratta to Tacrolimus
This is a "connection" page, showing publications Robert Stratta has written about Tacrolimus.
Connection Strength
0.716
-
Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Lo A, Kizilisik AT, Nezakatgoo N, Gaber LW, Gaber AO. Long-term experience with simultaneous kidney-pancreas transplantation with portal-enteric drainage and tacrolimus/mycophenolate mofetil-based immunosuppression. Clin Transplant. 2003; 17 Suppl 9:69-77.
Score: 0.220
-
Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant. 2002 Feb; 16(1):60-8.
Score: 0.207
-
Farney A, Sundberg A, Moore P, Hartmann E, Rogers J, Doares W, Jarrett A, Adams P, Stratta R. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant. 2008 Jan-Feb; 22(1):41-9.
Score: 0.078
-
Stratta RJ, Lo A, Shokouh-Amiri MH, Egidi MF, Gaber LW, Gaber AO. Improving results in solitary pancreas transplantation with portal-enteric drainage, thymoglobin induction, and tacrolimus/mycophenolate mofetil-based immunosuppression. Transpl Int. 2003 Mar; 16(3):154-60.
Score: 0.056
-
Gruessner RW, Burke GW, Stratta R, Sollinger H, Benedetti E, Marsh C, Stock P, Boudreaux JP, Martin M, Drangstveit MB, Sutherland DE, Gruessner A. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation. 1996 Jan 27; 61(2):261-73.
Score: 0.034
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):635-7.
Score: 0.028
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):641-3.
Score: 0.028
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):679-88.
Score: 0.028
-
Shaw BW, Markin R, Stratta R, Langnas A, Donovan J, Sorrell M. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. Transplant Proc. 1991 Dec; 23(6):2994-5.
Score: 0.026
-
Trofe J, Stratta RJ, Egidi MF, Lo A, Gaber LW, Shokouh-Amiri MH, Grewal HP, Honaker M, Hardinger K, Alloway RR, Gaber AO. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single centre experience. Clin Transplant. 2002; 16 Suppl 7:34-44.
Score: 0.013